We demonstrate that targeted expression of SV40 large T antigen (TAg) to the urethral (periurethral) and bulbourethral gland epithelium leads to adenocarcinoma formation in these tissues after 7 months of age, which are extremely rare sites for spontaneous tumor formation in humans. The development of proliferative lesions in the urethral gland predictably follows a temporal course of progression with approximately one third of male animals developing urethral tumors by 1 year of age. Tumor progression in these organs correlates to the level of TAg and p53 expression. Immunoprecipitation confirmed that SV40 TAg protein was bound to p53 and Rb p110 in vivo. Expression of transforming growth factor β (TGFβs) was evaluated during tumor progression of urethral gland carcinomas. Elevations of intracellular and extracellular TGFβ1 and extracellular TGFβ3 were found in preneoplastic and neoplastic lesions, suggesting that increased TGFβs may augment tumor growth. c-Met expression showed a tendency for increased expression in the urethral gland carcinomas. We speculate that the directed expression of SV40 TAg by the hormone responsive C3(1) gene and subsequent tumor formation in these organs is influenced by androgens, since these tissues and carcinomas express androgen receptor (AR) and arise only in male transgenic mice. Several cell lines established from the urethral carcinomas were also shown to express AR, but are not androgen dependent in culture. To our knowledge, this is the first transgenic animal model for urethral and bulbourethral carcinomas. This transgenic mouse model and the cell lines derived from it may provide a unique opportunity for dissecting molecular mechanisms involved in the tumorigenesis of these organs which otherwise rarely develop cancer.
We demonstrate that targeted expression of SV40 large T antigen (TAg) to the urethral (periurethral) and bulbourethral gland epithelium leads to adenocarcinoma formation in these tissues after 7 months of age, which are extremely rare sites for spontaneous tumor formation in humans. The development of proliferative lesions in the urethral gland predictably follows a temporal course of progression with approximately one third of male animals developing urethral tumors by 1 year of age. Tumor progression in these organs correlates to the level of TAg and p53 expression. Immunoprecipitation confirmed that SV40 TAg protein was bound to p53 and Rb p110 in vivo. Expression of transforming growth factor β (TGFβs) was evaluated during tumor progression of urethral gland carcinomas. Elevations of intracellular and extracellular TGFβ1 and extracellular TGFβ3 were found in preneoplastic and neoplastic lesions, suggesting that increased TGFβs may augment tumor growth. c-Met expression showed a tendency for increased expression in the urethral gland carcinomas. We speculate that the directed expression of SV40 TAg by the hormone responsive C3(1) gene and subsequent tumor formation in these organs is influenced by androgens, since these tissues and carcinomas express androgen receptor (AR) and arise only in male transgenic mice. Several cell lines established from the urethral carcinomas were also shown to express AR, but are not androgen dependent in culture. To our knowledge, this is the first transgenic animal model for urethral and bulbourethral carcinomas. This transgenic mouse model and the cell lines derived from it may provide a unique opportunity for dissecting molecular mechanisms involved in the tumorigenesis of these organs which otherwise rarely develop cancer.
Introduction
The development of tumors in the urethral or bulbourethral glands is an extremely rare event in humans (1) (2) (3) . This is in striking contrast to the incidence of human prostate cancer which is the most common tumor to occur in men in the US (4) . The differences between the frequency of tumor formation in these tissues is perplexing since these tissues arise from similar embryologic origins and are all androgen responsive. The rarity of urethral and bulbourethral gland carcinomas has led to speculation that these tissues are resistant to tumor formation. In this report, we demonstrate that these tissues are, indeed, able to spontaneously form tumors in vivo in C3(1)/TAg transgenic mice following the targeted expression of the simian virus 40 large T antigen (SV40 TAg*).
We have previously reported that C3(1)/TAg transgenic mice develop prostate and submandibular tumors in males and mammary tumors in females (5) . Male transgenic mice expressing SV40 TAg under the regulatory control of the rat prostatic steroid binding protein C3(1) 5Ј flanking region (6) develop prostate carcinomas beginning at 7 months of age (7) , whereas females develop mammary carcinomas after~4 months of age (8) . Further detailed histologic examination of these transgenic mice has revealed that in addition to the formation of tumors in the prostate and submandibular glands, male mice also develop tumors in the urethral and bulbourethral glands. However, no tumors were observed in the female urethral and submandibular glands, suggesting that the pattern of tumor formation in the male is androgen-related. We have analyzed the histogenesis of the unusual urogenital tumors as well as the submandibular tumors in male C3(1)/TAg transgenic mice. Furthermore, since aberrant expression of transforming growth factors β (TGFβs) have been reported in human prostate cancer (9) (10) (11) , expression of TGFβs isoforms was evaluated during progressive stages of urethral carcinoma development in the transgenic mice and found to be altered. Since abnormal expression of c-Met, the receptor of hepatocyte growth factor (HGF), has also been implicated in tumor progression of the prostate (12, 13) and other organs (14-16), c-Met expression was similarly examined. Urethral carcinoma cell lines developed from the transgenic tumors have also been established and characterized.
Materials and methods

SV40 TAg transgenic mice
Heterozygous C3(1)/TAg transgenic mice (5) were maintained by breeding with FVB/N nontransgenic mice. Transgenic animals were identified from mouse tail DNA by Southern and slot blot techniques utilizing a 32 P-labeled SV40-specific probe (5) . All manipulations of mice were performed in accordance with the guidelines of the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 1985) .
Development of cell lines from urethral gland carcinomas
Urogenital regions containing tumor were removed under sterile conditions. The majority of tissue specimens were examined histopathologically to determine the origin of each tumor. The remaining portion of the specimen was washed in phosphate-buffered saline (pH 7.4, Ca ϩϩ -free, Mg ϩϩ -free).
To establish cell lines, the tissue was minced into~1 mm 3 pieces, centrifuged and resuspended in growth media GM, which consists of PFMR-4A media (17) supplemented with 10 µg/l epidermal growth factor, 10 µg/l cholera toxin, 10 mg/l bovine pituitary extract, 4 mg/l insulin, 100 mg/l gentamycin, 1 µg/l hydrocortisone, 0.1 mM phosphoethanolamine, 3ϫ10 -8 M selenous acid, 2.3ϫ10 -6 M α-tocopherol and 3ϫ10 -11 M retinoic acid. Collagenase was added to 100 U/ml. After gently rocking overnight at 37°C, the suspension was centrifuged and plated on collagen coated dishes. To establish the fibroblastic cell line, a matching piece of tissue was minced into~1 mm 3 pieces, the suspension was centrifuged and resuspended in Dulbecco's modified Eagle's medium (DMEM) ϩ 10% fetal bovine serum (FBS) . For all cell cultures, the media was changed initially after 4 days and then weekly. After two passages, epithelial carcinoma cells were grown in DMEM ϩ 10% FBS. We established three carcinoma cell lines from the urethral gland: Ur12, and two subtypes of cell lines Ur22 E (typical epithelial phenotype) and Ur22 F (fibroblastic phenotype).
Histopathology
The C3(1)/TAg transgenic and nontransgenic mice were sequentially killed by CO 2 asphyxiation from 2 months to 1 year of age. The male accessory sex glands were dissected and fixed in 4% paraformaldehyde. Urethral glands from females were also examined. Salivary glands were removed from mice of both sexes. Two horizontal sections of the prostate containing the urethra and a sagittal section of each lobe of the bulbourethral glands were trimmed. Salivary glands were trimmed to include both submandibular and sublingual glands. Tissues were embedded in paraffin, cut at 4 µm thickness, and stained with H & E for histopathological evaluation.
Immunohistochemistry
The avidin-biotin complex (ABC) method was used for immunohistochemical analysis (Vectastain ABC Elite Kit, Vector Laboratories, Burlingame, CA). Unstained sections to be evaluated for SV40 TAg, p53 and proliferating cell nuclear antigen (PCNA) were immersed in distilled water and heated by microwave for antigen retrieval (18) . Anti-SV40 TAg mouse monoclonal antibody (PAb 101; PharMingen, San Diego, CA) was used at a dilution of 1:50; wild-type and mutant reactive anti-p53 sheep polyclonal antibody (Ab-7; Oncogene Science, Cambridge, MA) at a dilution of 1:500, and anti-PCNA mouse monoclonal antibody (PC-10; Dako Co., Carpinteria, CA) at a dilution of 1:500. Expression of the TGFβ1 and β3 isoforms and c-Met were also evaluated during tumor progression of the urethral gland carcinomas. The TGFβ isoforms were analyzed using three previously characterized antirabbit polyclonal Abs (19, 20) . The LC Ab (dilution at 1:400) reacts with an intracellular form of TGFβ1, staining cells that are actively synthesizing TGFβ1. The CC Ab (dilution at 1:1000) reacts with the extracellular form of TGFβ1; this Ab also exhibits some cross-reactivity with extracellular TGFβ3. The Eva Ab (dilution at 1:150) reacts specifically with an epitope of the mature form of extracellular TGFβ3. The dilution used gave a final IgG concentration of 2-3 µg/ml. Met expression was determined using rabbit polyclonal anti-Met C260 (dilution at 1:50). Donkey anti-rabbit IgG conjugated to fluorescein isothiocyanate (FITC) was used as the secondary antibody to c-Met and visualized by fluorescence using a Zeiss LSM confocal microscope.
In situ hybridization
Construction of the pGTag plasmid used to generate the probe for the SV40 early region has previously been described (7) . The plasmid was linearized with KpnI to generate a template for the antisense probe or with SacI to generate a template for the sense probe. [ 35 S]CTP-labeled 2.4-kb sense and antisense RNA probes were generated by runoff transcription with Sp6 or T7 polymerase. In situ hybridization was performed as described previously (21) . Briefly, histological sections were deparaffinized and hydrated, blocked in acetic anhydride and succinic anhydride, and hybridized overnight with riboprobes. Following RNase digestion and stringent washings, the slides were coated with Kodak NTB2 emulsion and incubated in the dark for 4 days. The slides were then developed in diluted D-19, fixed, and viewed with transmitted or darkfield illumination.
Immunoprecipitation and Western blotting
Tissues were homogenized and lysed with Triton X-100 (1.0% Triton X-100/ 50 mM Tris-HCl, pH 8.0/150 mM NaCl) buffers containing 100 µg/ml PMSF, 1 µg/ml aprotinin and 180 µg/ml sodium orthovanadate. Cells were scraped, rinsed and lysed in the above solution. Extracts were then cleared by centrifugation, and protein concentrations were determined by the Bradford assay (Bio-Rad, Hercules, CA). Whole-cell lysates were incubated with anti-SV40 TAg mouse monoclonal Ab (Ab-2, Oncogene Science) for 1 h at 4°C. Immune complexes were collected on protein A-Sepharose beads (CL4B; Pharmacia LKB, Uppsala, Sweden), washed with Triton X-100 buffer, boiled in SDS-containing sample buffer, separated in 10% Tris-glycine gels and transferred onto nitrocellulose membranes. After blocking with 3% bovine 196 serum albumin, blots were incubated for 1 h at room temperature with Ab against TAg (Ab-2, at 1 µg/ml, Oncogene Science), p53 (Ab-3, at 1 µg/ml, Oncogene Science) or Rb (C-15, at 1 µg/ml, Santa Cruz Biotechnology, Santa Cruz, CA). The blots were then washed, incubated for 1 h at room temperature with horseradish peroxidase-conjugated goat anti-mouse IgG (Boehringer Mannheim, Indianapolis, IN) or anti-rabbit IgG (Caltag, San Francisco, CA). Autoradiography was performed using enhanced chemiluminescence (DuPont, Boston, MA).
Reverse transcriptase-polymerase chain reaction (RT-PCR) assay for androgen receptor (AR) gene
Total RNAs were isolated from tissues or cells and incubated with DNase I. RNAs (2 µg) were reverse transcribed using oligo(dT) [12] [13] [14] [15] [16] [17] [18] and then incubated with RNase H (SuperScript, Gibco BRL, Gaithersburg, MD). cDNA was amplified using a thermal cycler (PTC-100; M.J. Research, Inc., Watertown, MA): 35 cycles at 94°C for 1 min, at 58°C for 2 min, at 72°C for 3 min. The 5Ј primer used corresponds to AR mRNA nt 1065-1084 (5Ј-CGA CTA CTA CAA CTT TCC GCT-3Ј) and the 3Ј primer used corresponds to AR mRNA nt 1634-1615 (5Ј-TCA TCT CCA CAG ATC AGG CA-3Ј) (22) . Primers for the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene were used as an internal control. The primer sequences used were: 5Ј-GAG TAT GTC GTG GAG TCT AC-3Ј and 5Ј-GCA GGG ATG ATG TTC TGG G-3Ј (23) . The PCR products were directly analyzed by agarose gel electrophoresis and visualized by ethidium bromide. Testis RNA which was not reverse transcribed was used as a control for DNA contamination.
Results
Histogenesis
Urethral glands. The urethral glands are predominantly located in the pelvic urethra in both sexes and between one pair of the bulbourethral glands in males. The histogenesis of the urethral gland carcinomas is shown in Figure 1 . Temporal changes in the incidence of the preneoplastic and neoplastic lesions in the urethral glands are illustrated in Figure 2A .
The submucosa of the urethra consists of fibrous and cavernous vascular tissues, and lobules of urethral gland acini ( Figure 1A ) with short excretory ducts opening into the urethral lumen. Normal glands are composed of cuboidal epithelial cells with oval nuclei in basal cells with secretory granules occasionally visible in the cytoplasm. There were no histologic differences observed in normal urethral glands at various ages. In this experiment, no proliferative lesions or tumors were observed in wild-type male mice. Early epithelial hyperplasias (not atypical) of urethral glands, seen as a slightly increased number of small ducts, were observed at 2 months of age. Atypical hyperplasia ( Figure 1B ) developed in all mice by 4 months of age and was composed of increased numbers of irregularly structured ducts exhibiting nuclear hyperchromatism and atypism. Apoptotic bodies were frequently seen in this lesion. Atypical nodular hyperplasia, composed of a markedly increased cell population with nodular patterns, or, occasionally, a micropapillary pattern, was noted by 5-6 months of age. Nuclear chromatin within the atypical nodular hyperplasias was increased in density and clumping of chromatin and apoptotic bodies were common. As animals aged, multiple atypical nodular lesions were observed, suggesting that a transition occurs from atypical hyperplasias to nodular lesions.
Lesions exhibiting invasion into the surrounding stroma were diagnosed as adenocarcinomas. Cellular pleomorphism such as nuclear irregularity and varied size was much more pronounced in carcinomas than in atypical nodular lesions. Adenocarcinomas developed after 7 months of age and the incidence continued to increase with age. One carcinoma in a 10 month old mouse contained chondrocytes and cartilage formation. Table I shows the extent of invasiveness and incidence of metastasis to distal sites. All carcinomas of the urethral glands showed invasion into the ischiocavernosus muscle, and invasion into adjacent tissues (Table I) . Aggressive urethral gland carcinomas tended to be poorly differentiated with a spindle cell phenotype. Invasion to adjacent tissues was occasionally observed (Table I, footnote) . Distant metastases to the lungs were also seen ( Figure 1D ) (Table I ). In contrast to the males, no proliferative lesions were seen in the urethral glands of the female transgenic mice. Bulbourethral glands. Temporal changes in the incidence of lesions of the bulbourethral glands are presented in Figure 2B . Normal bulbourethral glands are predominantly composed of mucous glands and a central duct ( Figure 3A) . In wild-type mice at all ages, acini are lined by one layer of pyramidal cells with pale, basophilic cytoplasm as demonstrated by H & E staining, and no proliferative lesions were seen. Atypical hyperplasias ( Figure 3B ) were seen by 5-6 months of age and adenocarcinomas ( Figure 3C ) were observed by 7 months of age. Their histologic pattern was similar to that of the urethral gland lesions. However, the development of lesions in the 197 bulbourethral glands was much more independent of aging than those of the urethral gland. Metastasis to the lung was found in only one case in an animal at 9 months of age (Table  I) . Chondrocyte formation was occasionally seen in invading tumors within the ischiocavernosus muscle but not within the bulbourethral glands themselves ( Figure 3D ). Salivary glands. The incidence of submandibular gland lesions and metastasis in the C3(1)/TAg transgenic males are shown in Table II . No spontaneous lesion was observed in salivary glands of any wild-type mice. Ductular atypical hyperplasias (see asterisk in Figure 4E ), composed of irregularly structured ducts with cellular atypism, were seen in the submandibular glands of the transgenic males at 3 months of age. By 5-6 months of age, atypical nodular hyperplasias (see arrows in Figure 4E ) were observed and could also be referred to as microadenomas. Adenocarcinomas of the submandibular glands developed at 8 months of age (see Figure 4B ). Submandibular gland adenocarcinomas were found in 60% of transgenic males surviving Ͼ10 months of age. Some of the adenocarcinomas showed metastases to the lung (Table II) . Occasionally, minimal nuclear atypism was observed in sublingual glands but no tumors were found in the sublingual glands of transgenic males at any age. In contrast to the transgenic males, only focal minimal nuclear atypism was observed in the submandibular glands of the transgenic females at 5-6 months of age. Unlike the males, no atypical lesions or tumors were observed in female salivary glands. Figure 4A ) and markedly increased in atypical modular lesions in all of these organs. Most of the carcinoma cells in these glands expressed high levels of TAg protein ( Figure 4B ). This finding is consistent with the results obtained by in situ hybridization for TAg mRNA where strong signals were detected specifically within proliferative lesions ( Figure 4C and D) . The pattern of p53 protein expression was similar to that for TAg expression in normal tissues and in lesions of the urethral/bulbourethral and submandibular glands ( Figure 4E and F). PCNA immunoreactive cells were markedly elevated in atypical lesions and carcinomas, whereas normal areas showed few positive cells (Table III) .
Expression of TGFβs and c-Met proteins
Lesions of the urethral glands were further analyzed for expression of TGFβs and c-Met. The intracellular form of TGFβ1 was weakly expressed in normal urethral glands ( Figure  5A ) independent of the age of the mice, but accumulation of the intracellular TGFβ1 was observed in most preneoplastic ( Figure 5B ) and neoplastic lesions ( Figure 5C ). Although extracellular TGFβ1 protein was barely detectable in normal urethral glands ( Figure 5D ) in mice at all ages examined, this form of TGFβ1 was increased in atypical lesions ( Figure 5E ) and carcinomas ( Figure 5F ). However, carcinomas showed some variations in the expression of extracellular TGFβ1. TGFβ3 (extracellular) was weakly expressed in normal urethral glands ( Figure 5G ) at all ages, was increased in atypical lesions ( Figure 5H ) and markedly elevated in carcinomas ( Figure 5I ). c-Met protein was weakly detected in normal urethral glands ( Figure 5J ). Carcinomas, however, often demonstrated elevated c-Met expression ( Figure 5K ), although there were large variations.
p53 and pRb Complexes with SV40 TAg
As shown in Figure 6 , immunoprecipitation and Western blotting demonstrated the expression of the expected 94 kDa SV40 TAg protein in carcinomas of the urethral and submandibular glands, and urethral gland carcinoma cell lines (Ur12 and Ur22 E ) carrying SV40 TAg transgene. In addition, p53 (53 kDa) and pRb (110 kDa) proteins complexed with SV40 TAg protein were found in these carcinomas and the carcinoma cell lines. No such p53 or pRb complexes with SV40 TAg were found in normal submandibular gland of wild-type.
RT-PCR for AR gene expression
Expression of AR by RT-PCR is presented in Figure 7 . Urethral gland carcinoma cell line Ur22 E expressed low levels of AR which was barely detectable in Ur22 F cells. No AR expression was detectable by RT-PCR in the Ur12 line at passage 10.
Growth of the tumor cell lines did not appear to be androgendependent since the cell lines grew well in the absence of 
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androgen. However, carcinomas of the urethral glands showed AR gene expression in vivo, but at relatively low levels ( Figure  7 , lane UrCa). Normal bulbourethral glands expressed the AR gene. AR was expressed in normal submandibular glands of both sexes as well as in the carcinomas.
Discussion
Although the incidence of prostate cancer has been increasing annually in the US and is now the leading cause of cancer among men (4), neoplasms of the urethral and bulbourethral glands remain extremely rare (1-3). The discrepancy in the incidence of cancer development in these organs, which are derived from common embryologic origins, remains unknown. We have demonstrated that the targeted expression of the SV40 TAg in the urethral and bulbourethral epithelia is capable of inducing tumor formation in these tissues. The endogenous C3(1) gene is highly expressed in the rat ventral prostate and lower levels of expression occur in the a One case of histiocytic sarcoma was also observed at 8 months of age which showed metastasis to lung and liver. Parentheses indicate percentage incidence. Grading of protein expression: -, negative (0%); Ϯ, rare (Ͻ0.1%); 1ϩ, mild (Ͻ10%); 2ϩ, moderate Ͻ50%); 3ϩ, strong (Ͼ70%); 4ϩ, very strong (Ͼ90%).
dorso-lateral lobes (24) . A similar pattern of TAg expression is seen in the prostate lobes of the C3(1)/TAg transgenic mice (7) . In this study, TAg expression was also seen in the androgen-responsive urethral, bulbourethral and submandibular glands, indicating that C3(1) regulatory regions used in the transgenic construct may respond to androgen stimulation in these organs. Chondrocyte or cartilage formation was seen in the urethral gland carcinomas and tumors invading into the ischiocavernousus muscle. Sweat glands of the feet of the C3(1)/TAg transgenic mice have also been noted to develop mixed tumors with chondrocyte formation (25) . Mixed tumors of human salivary glands frequently contain chondrocyte development. However, such formation was not frequently seen in the submandibular gland tumors of this model. The cartilage containing tumors in this transgenic model may form as the result of the secretion of a bone morphogenetic protein of the TGFβ superfamily. We are currently addressing this issue experimentally. SV40 TAg expression was detected at very low levels in normal-looking epithelial cells of the urethral, bulbourethral and salivary glands. However, the TAg expression in all three of these tissues increased in atypical lesions and was markedly elevated in carcinomas. The pattern of p53 expression was similar to that of TAg expression. Immunoprecipitation with anti-SV40 TAg Ab confirmed that TAg protein actually binds to p53 and Rb p110 in vivo, as has previously been demonstrated (26, 27) . The transforming activity of SV40 TAg has been linked to its ability to bind to and functionally inactivate p53, pRb and its related proteins p107 and p130 (26) (27) (28) . Inactivation of p53 and pRb functions by SV40 TAg appears to be functionally equivalent to the mutation or loss of these tumor suppressor genes, as is frequently seen in neoplasias of human and experimental animals. The unphosphorylated form 201 of pRb has been demonstrated to suppress the cell cycle at the G1/S transition (29) . We demonstrated by immunoprecipitation that it is the unphosphorylated form of pRb which binds to TAg in the transgenic tumors. This may be a mechanism which contributes to transformation in these tissues. However, further experiments are needed to examine pRb-related p107 and p130 status during tumorigenesis.
PCNA, a cyclin or DNA polymerase δ-associated protein, is synthesized in early G1 and S phases of the cell cycle and serves as an excellent marker for proliferating cells (30) . PCNA expression correlated to the severity of the lesions in the urethral/bulbourethral and salivary glands.
The abnormal expression and response to TGFβ by epithelial tumors has been well established (9) (10) (11) . We, therefore, wished to determine whether aberrant expression of TGFβs was associated with the development of the transgenic urogenital tumors. The most abundant isoform of TGFβs in mammalian species is TGFβ1 (31) . This form has been reported to be a suppressor of epithelial cell growth (32, 33) . Paradoxically, it also has potential tumor growth-enhancing properties (34) (35) (36) . The stimulation of tumor growth might be due to immune suppression, autocrine or paracrine effects, or stimulation of angiogenesis by TGFβ1 (37) (38) (39) . With respect to urogenital carcinomas, TGFβ1 levels are markedly increased in the Dunning rat prostate carcinoma model (40) , are elevated in poorly differentiated carcinomas using the mouse prostate reconstitution model (41) , and often increased in human prostate cancers (9, 42) . In the present study, the elevated TGFβ1 levels appeared to be associated with the transition from atypical lesions to carcinomas in the urethral gland. Previous reports suggest that TGFβ3 is expressed in fibroblasts (43) and may be involved in maintenance of the spindle cell phenotype (44) . Since the advanced urethral gland carcinomas frequently were of a poorly differentiated type composed of spindle cells, the up-regulation of TGFβ3 might influence the development of the spindle cell phenotype in these transgenic tumors. Further work is required to determine the status of the receptors for TGFβ which may also be altered during tumor progression.
The c-met protooncogene encodes a tyrosine kinase receptor of 190-kDa protein c-Met. HGF is the ligand of the c-Met receptor (14, 45, 46) . c-Met has been implicated in epithelial embryogenesis and tumor progression in various organs including the prostate (12) (13) (14) (15) (16) . In the present study, urethral gland carcinomas tended to have increased levels of c-Met, although this was very variable. Therefore, elevated c-Met expression does not appear to be critical in transformation of these transgenic urogenital epithelial tumors.
Growth and differentiation of urethral and bulbourethral glands are androgen-dependent (47) . Urethral and bulbourethral glands in men are homologous to female Skene's (periurethral) glands and Bartholin's glands, respectively (48) . Neoplasms of these glands in women are also rare (3). Unlike the male mice, lesions in the female glands were not observed in the C3(1)/TAg transgenic mice. In addition, lesions in the female salivary glands were limited to minimal nuclear atypia compared to male transgenic mice of the same age, which developed much more extensive lesions. This pattern of tumor formation suggests a role for androgens in the development of urethral, bulbourethral and salivary gland tumors in this transgenic mouse model. However, since the normal salivary glands of females also express AR as reported previously (49), it remains unclear why salivary gland tumors did not develop in female transgenic mice. We speculate that low levels of circulating androgens in females compared to males may account for this difference. This is consistent with the fact that the mouse submandibular gland is sexually dimorphic. The conspicuous difference between the male and female submandibular glands is largely due to the much greater abundance of intensely eosinophilic secretory granules in the male ductal cells which are large columnar cells with basally Maintenance of in vitro tumor cell growth did not appear to be androgen-dependent since the cell lines were grown in the absence of androgen. In this study, AR expression was not detected in urethral gland carcinoma cell line Ur12 (passage 10) by RT-PCR under the present conditions, whereas Ur22 E and Ur22 F had low levels of AR expression. Progression of human prostate cancer from an androgen-dependent to an androgen-independent state is a well established phenomenon (50) . Urethral gland carcinomas appeared to express low levels of AR but we could not compare AR expression levels between normal and carcinoma cells by RT-PCR, since normal urethral glands are microscopic and could not be isolated. This issue might be further approached using immunohistochemical techniques for the detection of AR.
To our knowledge, an animal model for carcinomas of the urethral and bulbourethral glands has not previously been reported. These unusual tumors, especially urethral gland tumors, develop predictably over time and become aggressive, as demonstrated by their propensity for invasion into adjacent tissues. These transgenic mice and the cell lines derived from them are unique models for dissecting the molecular mechanisms which occur during tumorigenesis in these organs which otherwise seem refractory to tumor formation. Fig. 7 . RT-PCR analysis of androgen receptor (AR) mRNA levels in urethral, bulbourethral and submandibular glands and urethral gland carcinoma cell lines. UrCa, urethral gland carcinoma, transgenic, 10 month old; Ur12, Ur22 F and Ur22 E , urethral gland carcinoma cell lines; BuN, normal bulbourethral gland, non-transgenic, 4 month old; SmCaɉ, normal submandibular gland, non-transgenic male, 4 month old; SmNɊ, normal submandibular gland, non-transgenic female, 4 month old. cDNA from testis and liver was used as positive controls for differential levels of AR gene expression. Testis RNA (not reverse transcribed to cDNA) was used as a negative RT-PCR control. Since testis RNA did not demonstrate a PCR amplification product, no significant DNA contamination was observed. Carcinomas of the urethral gland showed AR expression. Urethral gland carcinoma cell lines Ur22 F and Ur22 E showed low levels of expression, whereas AR was not detected in Ur12. Submandibular glands exhibited strong expression of AR independent of the presence of lesions and sex. GAPDH was used as an internal control.
